Aidoc's CARE1™ — first foundation-model clinical AI cleared
In February 2025, the FDA cleared Aidoc's CARE1 — the first foundation-model-powered clinical AI to receive U.S. authorization.
A next-generation healthcare technology platform — powered by 40 years of clinical field expertise and 15 years of AI & software engineering. We scout, validate, and bring world-class medical AI to Türkiye and the region.
From radiology to robotic surgery, from wound care to predictive medicine — we follow the technologies that will define the next decade of healthcare and bring the most promising ones into clinical use.
The medical AI market is full of brilliant algorithms with no clinical grounding. We are the inverse: deep operational experience in Turkish healthcare, paired with serious AI engineering.
Forty years of medical device distribution, hospital relationships, surgeon networks and KOL access — built by Bilgin Tıp Medikal and sister company Hekimsan Sağlık. This is the foundation.
Datailor Technology brings 15+ years of AI and software engineering — not vibes, not demos. Production systems, real datasets, and the discipline to validate before deploy.
For foreign AI medtech firms, we are the bridge into Türkiye and the wider region: regulatory guidance, pilot hospitals, commercialization, reimbursement strategy, and a clinical network that can validate technology in real-world environments.
A curated read of recent FDA & CE approvals, clinical validations, fundings, and acquisitions.
In February 2025, the FDA cleared Aidoc's CARE1 — the first foundation-model-powered clinical AI to receive U.S. authorization.
April 2025: Paige received FDA Breakthrough Device designation for PanCancer Detect — the first AI tool to identify both common and rare cancer variants across multiple tissue types.
ISC 2025 evidence: in 1,600+ hospitals, Viz.ai's LVO triage shortens CT-to-EVT timing and re-routes patients faster.
FDA AI-enabled medical device authorizations have crossed 1,450. Radiology accounts for three-quarters of them.
RauMed evaluates partnerships, distribution, pilots, joint ventures and localization for healthcare AI companies entering Türkiye and the region.